Ery-Tab (Erythromycin)

Ery-Tab (Erythromycin) is filed as Macrolide Antibiotic. The sections below restate public label fields stored for this profile.

Class
Macrolide Antibiotic
Generic name
Erythromycin
Route
TOPICAL
Dosage forms
HOW SUPPLIED Erythromycin Tablets, USP 250 mg are light pink, film coated, oval shaped tablet, debossed with "||||"on one side and plain on the other side and are supplied as follows: NDC 70710-1047-3 in bottles of 30 tablets with child-resistant closure. NDC 70710-1047-1 in bottles of 100 tablets with child-resistant closure. NDC 70710-1047-5 in bottles of 500 tablets. Erythromycin Tablets, USP 500 mg are light pink, film coated, oval shaped tablet, debossed with "1048" on one side and plain on the other side and are supplied as follows: NDC 70710-1048-3 in bottles of 30 tablets with child-resistant closure. NDC 70710-1048-1 in bottles of 100 tablets with child-resistant closure. NDC 70710-1048-5 in bottles of 500 tablets. Recommended storage Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.]
Generic available
Yes
Manufacturer
Bryant Ranch Prepack

Approved uses

INDICATIONS AND USAGE Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris.

How it works

CLINICAL PHARMACOLOGY The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug. Microbiology – Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated in vitro between erythromycin, lincomycin, chloramphenicol, and clindamycin.

Warnings and precautions

WARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.

Contraindications

CONTRAINDICATIONS Erythromycin Topical Solution USP, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Adverse reactions

Erythromycin has been associated with QT prolongation and ventricular arrhythmias, including ventricular tachycardia and torsades de pointes. (See WARNINGS ). Side effects following the use of intravenous erythromycin are rare. Occasional venous irritation has been encountered, but if the infusion is given slowly, in dilute solution, preferably by continuous intravenous infusion or intermittent infusion in no less than 20 to 60 minutes, pain and vessel trauma are minimized. Allergic reactions ranging from urticaria to anaphylaxis have occurred. Skin reactions ranging from mild eruptions to erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported rarely. There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency and in patients receiving high doses of erythromycin. Elderly patients, particularly those with reduced renal or hepatic function, may also be at increased risk for developing this effect when Erythrocin TM doses of 4 grams/day or higher are given (See DOSAGE AND ADMINISTRATION ).

Dosage and administration

DOSAGE AND ADMINISTRATION Erythromycin Topical Solution USP, 2% should be applied over the affected areas twice a day (morning and evening) after the skin is thoroughly washed with warm water and soap and patted dry. Acne lesions on the face, neck, shoulders, chest, and back may be treated in this manner. This medication should be applied with applicator top. If fingertips are used, wash hands after application. Drying and peeling may be controlled by reducing the frequency of applications.

Drug interactions

Drug Interactions Serious adverse reactions have been reported in patients taking erythromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin and atorvastatin; and hypotension with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) (see PRECAUTIONS - Drug Interactions ). There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine. This interaction is potentially life-threatening and may occur while using both drugs at their recommended doses (see PRECAUTIONS - Drug Interactions ). Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin. Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels. (See package insert for lovastatin).

Common questions

What is Ery-Tab approved to treat?

According to its FDA label, Ery-Tab (Erythromycin) is approved for: INDICATIONS AND USAGE Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris. For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Ery-Tab?

Ery-Tab (Erythromycin) belongs to the Macrolide Antibiotic class of medications.

What form does Ery-Tab come in?

The FDA label lists Ery-Tab (Erythromycin) as: HOW SUPPLIED Erythromycin Tablets, USP 250 mg are light pink, film coated, oval shaped tablet, debossed with "||||"on one side and plain on the other side and are supplied as follows: NDC 70710-1047-3 in bottles of 30 tablets with child-resistant closure. NDC 70710-1047-1 in bottles of 100 tablets with child-resistant closure. NDC 70710-1047-5 in bottles of 500 tablets. Erythromycin Tablets, USP 500 mg are light pink, film coated, oval shaped tablet, debossed with "1048" on one side and plain on the other side and are supplied as follows: NDC 70710-1048-3 in bottles of 30 tablets with child-resistant closure. NDC 70710-1048-1 in bottles of 100 tablets with child-resistant closure. NDC 70710-1048-5 in bottles of 500 tablets. Recommended storage Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.]; topical route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Ery-Tab?

Yes. A generic version of Ery-Tab (Erythromycin) is available in the U.S. Ask your pharmacist about substitution.

Does Ery-Tab have a Boxed Warning?

Our ingest of the FDA label for Ery-Tab (Erythromycin) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Ery-Tab cost?

Public CMS NADAC pricing for Ery-Tab (Erythromycin) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Ery-Tab currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Ery-Tab (Erythromycin) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Ery-Tab approved by the FDA?

The FDA record lists the approval date for Ery-Tab (Erythromycin) as 1991-01-11.

Who makes Ery-Tab?

The FDA label lists Bryant Ranch Prepack as a labeler/manufacturer of Ery-Tab (Erythromycin). Multiple firms may market generics of the same molecule.

How should Ery-Tab be stored?

The FDA label states: "Store in a dry place at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]." Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…